# A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

> **NCT02990325** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abivax S.A.** · enrollment: 36 (actual)

## Conditions studied

- HIV Infections
- Health Volunteers

## Interventions

- **DRUG:** ABX464 150mg
- **DRUG:** ABX464 50mg
- **DRUG:** ABX464 50mg

## Key facts

- **NCT ID:** NCT02990325
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-27
- **Primary completion:** 2018-12-27
- **Final completion:** 2019-10-21
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02990325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02990325, "A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02990325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*